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The role of the liver cytosolic factor in the
development of vitamin D3 25-hydroxylase activity has been
examined in fetuses and their mothers. 25-Hydroxyvitamin D3
production was measured in liver microsomes from fetuses
three days prior to parturition and on the expected day of
parturition. Production rates were low three days prior to
birth (0.11 pmol/g liver/hour) and increased to 1.2 pmol/g
liver/hour on day zero. Production rates in mothers three
days prior to fetal birth and on day zero were 5.4 pmol/g
liver/hour and 9.3 pmol/g liver/hour, respectively. The
liver cytosolic factor was present as early as three days
prior to birth. The factor was obligatory for 25-
hydroxylase activity in the fetuses examined and was able to
stimulate the 25-hydroxylase activity of the mothers up to
1
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1.7 fold. It was also capable of preventing non-specific
degradation of vitamin D3. These observations and the
finding that 25-hydroxylase activity reaches full activity
near the weaning stage suggest that the limiting factor in
the maturation of vitamin D3 25-hydroxylase activity in
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Vitamin D3 (cholecalciferol) is essential for life in
higher animals. It is one of the principal biological
regulators of calcium metabolism.^ Vitamin D and two
peptide hormones, calcitonin and parathyroid hormone, are
responsible for the maintenance of calcium homeostasis.
Vitamin D3 and parathyroid hormone act synergistically to:
1) increase calcium bone resorption;
2) increase calcium absorption in the intestine;
and;
3) increase renal calcium absorption and
phosphorus excretion.
Calcitonin acts inversely.by blocking bone resorption (of
both calcium and phosphorus) and inhibiting osteoclast
formation. This results in a decrease in serum calcium and
phosphorus levels. The requirement for vitamin D is
apparent when one observes the various manifestations that
occur in its absence. The afflictions that arise range from
those that act at the systemic level, at specific organs, or
those that are only manifest at the subcellular levels.
Rickets and osteomalacia are the two main diseases resulting
from vitamin D deficiency. They were once prevalent, but
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the incidence has been greatly reduced due to vitamin D
supplementation of various food products. Major efforts are
continually being made to understand the biological and
physiological modes of action of this vital substance.
Vitamin D must be converted to metabolically active
forms before it can function. Vitamin D3 is normally made
in the skin of humans and animals from an inactive
precursor, 7-dehydrocho1estero1. Pre-vitamin D3 is
synthesized from 7-dehydrocholesterol by reactions that are
promoted by exposure to the ultraviolet component of
sunlight. Over a period of days, pre-vitamin D3 undergoes a
temperature dependent thermal isomerization to form vitamin
03.'^ Pre-vitamin D3 is not bound by the plasma transport
protein for vitamin D3, but vitamin D3 is transported to the
liver bound to a plasma transport protein.
Vitamin D3 is absorbed with fats in the small intestine
through the lacteal system. Bile salts are required for
this process.
Sixty to eighty percent of vitamin D accumulates in the
liver in a specific manner. Predominantly in the liver, but
not exclusively, vitamin D3 is hydroxylated on carbon 25
(Figure 1) to produce the intermediate, 25-hydroxyvitamin
03.^“'® This reaction occurs in both liver microsomes^ and
10liver mitochondria.
3
25-Hydroxyvitaiiiin D, 1.2S'Dihydroxyvitamin D,
Figure 1. The synthesis of the hormone 1,25-dihydroxychole-
calciferol involves the successive action of three organs.
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In 1966, Lund and DeLuca^^ demonstrated the existence
of 25-hydroxyvitamin D3 as a polar metabolite of vitamin D
and possibly as the metabolically active form. This
metabolite, which was able to cure rickets in rats with the
same effectiveness as vitamin D, has been demonstrated in
human plasma,porcine plasma,and chicks.Further
study revealed that this metabolite fraction initiates bone
mobilization and intestinal transport of calcium.Its
effect on calcium transport was suggested to be more rapid
than that of vitamin Stohs and DeLuca^^ demonstrated
that this metabolite was virtually the exclusive form of
vitamin D in the intestinal nuclei prior to the initiation
of biochemical events leading to the increase in calcium
transport. However, in 1971, Holick Bt al^® isolated and
identified the compound 1,25-dihydroxycholecalciferol as the
definitive "tissue active" metabolite of vitamin D in the
intestine.
A specific vitamin D 25-hydroxylase is located in the
microsomes. It requires NADPH, molecular oxygen, and
magnesium ions. This system is suppressed by prior
administration of vitamin D to vitamin D-deficient animals.
This regulation does not have great physiological
significance because deficiency only results in a two-fold
difference in activity of the 25-hydroxy 1 ase.
Solubilization and subsequent reconstitution of this enzyme
system^^ indicates the involvement of a flavoprotein, an
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NADPH-dependent cytochrome P-450 reductase, and a cytochrome
P-450 component which is the enzyme directly involved in the
hydroxylation (Figure 2).
Cytochrome P-450 plays a significant role in many
biological hydroxylation reactions. It serves as the
terminal-oxygen-activating enzyme in the reactions. The
term mixed-function-oxidase has been used to describe these
enzymes. Mixed function oxidases are enzymes that catalyze
the simultaneous oxidation of two substrates by molecular
oxygen, one of which is usually NADPH or NADH. Evidence for
the involvement of cytochrome P-450 in the 25-hydroxyl at ion
reactions has been derived by studies showing: a) the
inhibition of enzyme activity by carbon monoxide,^® b) the
photoreversibility of the carbon monoxide inhibition,c)
inhibition by drugs such as metyrapone,^^^^ d) the
inhibition of other cytochrome P-450-dependent reactions by
cholecalciferol and 25-hydroxyvitamin 03,^^ and e)
phenobarbital induction.Microsomal cytochrome P-450
linked function oxidase systems can be classified into two
types: 1) a single electron transport system of NADPH or
NADH as an electron donor, or 2) a conjugated electron
transport system with NADPH and NADH as electron donors.
The vitamin D3 25-hydroxylase microsomal system is
classified as a single electron transport system.^^
The microsomal 25-hydroxylase in rat liver has an
apparent of 44 nM.^^ This system is of low capacity.
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Vitamin D-25 hydroxylase
25 OH Vitamin D Vitomin D
Figure 2. Components in the vitamin D-25-hydroxylase
system in liver microsoroes.
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high affinity and is important when vitamin D3
concentrations are low or physiological.^® Due to the
microsomal system being stimulated in the rachitic state, it
is probable that this system is of regulatory importance
with respect to vitamin D3 metabolism.^”
In addition to the microsomal 25-hydroxylase, a vitamin
D3 25-hydroxylase is known to exist in mitochondria. It
also requires NADPH and oxygen. The enzyme is not specific
for vitamin D3 since it hydroxylates cholesterol in the 25
and 26 positions. Activity of the crude enzymes is
unaffected by the vitamin D status, but vitamin D-deficiency
increased the activity of a reconstituted vitamin D3
hydroxylase two-to-four-fold.^® Solubilization and
reconstitution experiments demonstrate that the
t . . ^ ft
mitochondrial 25-hydroxylase enzyme is a cytochrome P-450.
This 25-hydroxylase requires NADPH, is inhibited by carbon
monoxide, and can be stimulated by phenobarbital. Oxygen-
18 is incorporated in position 25 from ^®02. Phenobarbital
induction increased the activity of the rat mitochondrial
vitamin D3 25-hydroxylase far more markedly than that of the
rat microsomal vitamin D3 25-hydroxylase.It has
also been shown that a cytochrome P-450 fraction solubilized
from rat liver mitochondria was able to catalyze 25-
hydroxy lation of vitamin D3 when combined with NADPH
ferredoxin and ferredoxin reductase.
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An apparent Kjjj of 10 uM has been determined for the
mitochondrial enzyme in rat liver.This system is of high
capacity and low affinity, thus making it more important at
high substrate levels of vitamin 03.^® The physiological
importance of the mitochondrial system for the 25-
hydroxylation of vitamin D3 is not readily known at this
time.28
25-Hydroxyvitamin-D3 is further hydroxyl ated in
position one to produce 1 alpha, 25-dihydroxyvitamin D3, the
metabolically active form of vitamin D (Figure 1). This
reaction takes place exclusively in the kidney in non¬
pregnant mammals. In the pregnant mammal the placenta is a
site of hydroxylation.
The 1 alpha-hydroxylase reaction is perhaps the most
significant in the metabolism of vitamin D. Activity of
this hydroxylase is regulated by the need for calcium or
phosphorus and this step must be regarded as the major
regulatory step in the metabolism of the vitamin.®^'
Stimulation of this enzyme activity is promoted by low
plasma calcium concentrations, low plasma phosphorus
concentrations, and a vitamin D-deficient state.
The 1 alpha-hydroxylase has been studied extensively in
the chick kidney. It requires NADPH. The hydroxylase has
been solubilized and reconstituted successfully. The system
involves NADPH reduction of a flavoprotein, renal ferredoxin
reductase, which in turn reduces an iron sulfur protein
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called renal ferredoxin.^^”^^ The renal ferredoxin then
supplies reducing equivalents to the cytochrome P-450 that
is the hydroxy 1 ating enzyme.Of the components
involved, only the renal ferredoxin reductase has been
purified to homogeneity.It is a protein of molecular
weight 11,800 and contains a two-iron, two sulfur
cluster.34-36
Another reaction that has received a great deal of
attention is the 24-R hydroxylation pathway. The metabolite
24-R, 25-dihydroxyvitamin D3 was found in human^^ and animal
plasma.3®”40 less biological activity than 25-
hydroxyvitamin D3. Nevertheless, its presence in large
amounts in biological fluids and the fact that its level is
regulated inversely from that of 1,25-dihydroxyvitamin D3
has led to many experiments concerning its possible
functional importance and biological role.^^ Factors that
stimulate 24-R hydroxylase activity are high plasma calcium
concentrations, high phosphorus concentrations, and a
vitamin D-replete state. The 24-R hydroxylase is a
cytochrome P-450 dependent reaction42 which occurs not only
in kidney, but also in intestine, cartilage, and bone.4^»44
Numerous other reactions of vitamin D metabolism exist.
To date more than seventeen metabolites of vitamin D3 have
been isolated (Figure 3).4^
There are several functions for vitamin D. The active
form of the vitamin, 1 alpha, 25-dihydroxyvitamin D3,
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Figure 3. Some metabolites of vitamin .
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functions in the regulation of intestinal calcium absorption
and in the mobilization of calcium from bone. The molecular
mechanism of action of l,25-(OH)2D3 in the intestinal villus
cell is illustrated in Figure 4 where 1,25-(OH)2D3,
calcitriol, interacts with a receptor in the nucleus or in
the cytosol which ultimately appears in the nucleus. This
results in expression of genes that code for calcium binding
protein (CaBP), a transport protein that facilitates the
transfer of calcium across the villus. Calcium is then
expelled at the basal lateral membrane in a sodium dependent
process.1,25-Dihydroxyvitamin D3 also stimulates
intestinal phosphate transport.^ ^® The molecular
mechanism of this transport process is unknown. The main
role of vitamin D is the maintenance of serum calcium
levels.’^ Under low calcium and vitamin D-deficient
conditions, there is a need to increase calcium levels.
This can be accomplished by the mobilization of calcium into
plasma from the bone. This mobilization requires the action
of 1,25-(0H)2D3 in concert with parathyroid hormone.
In view of our understanding of the complex metabolic
conversion of vitamin D3 to its hormonally active form, it
is not unreasonable to anticipate the existence of specific
binding proteins for the parent vitamin as well as its
metabolites.^
The vitamin D3 binding cytosolic protein is thought to
have a significant effect on the metabolism of vitamin D in
12
Figure 4. Mechanism of calcium transport in intestinal
mucosal villus cells in response to calcitriol.
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the liver. It is thought to be a necessary factor for the
activity of microsomal vitamin D3 25-hydroxylase. Vitamin
D3 is oxidatively degraded when cytosol is excluded from the
incubation mixture.® It is possible that the liver
microsomal lipid peroxidation system is responsible since
N,N - diphenyl-p-phenylenediamine (DPPD), an inhibitor of
that system, blocks the degradation of vitamin D3.®
Two distinct liver cytosolic binding proteins for
vitamin D3 and 25-hydroxyvitamin D3 have been partially
purified from chicks.One of the two proteins appears to
have a high selectivity for 25-OHD3 while the other binds
vitamin D3 as well as 25-01103.^^ The physiological role of
these hepatic proteins may include control of the
concentration of bound versus free metabolites and also
control of the rates of microsomal enzyme-dependent
conversions in the liver.
Development of the 25-hydroxylase enzyme system and
binding proteins are significant clinically. Clinical
studies have indicated that the human neonate metabolizes
drugs less effectively than the adult.^^ Experiments with
lower animals have shown that low levels of drug metabolism
throughout the gestational period can be correlated with low
concentrations of the components of the hepatic mixed-
function oxidase system.
In most species studied, birth appears to activate the
development of this system.^^ The developmental sequence of
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events varies with species and with the substrate
metabolized.^^ Because the microsomal and mitochondrial
vitamin D3 25-hydroxylases are cytochrome P-450 oxidases,
this suggests that 25-hydroxylase activity may be low or
absent in the preterm infant. Many clinical studies have
correlated 25-OHD3 levels with gestational age, suggesting
c 1
that 25-hydroxylation might be gestation dependent.^® In
one study oral or intravenous vitamin D supplementation did
not increase the circulating levels of 25-OHD3 in premature
infants until a post-conceptional age of 36-38 weeks.In
another study, a vitamin D supplement of 500 lU/d, given to
premature infants, was sufficient to improve their vitamin D
nutritional status as judged by the rising 25-OHD3 levels.
However, the plasma concentration of 25-OHD3 did not reach
adult levels until 5-10 weeks after birth.The median
level of plasma concentration of 25-OHD3 in 12 month old
infants did not differ significantly from the adult value,
but infants below 12 months had lower 25-OHD3 values than
that of adults.
Levels of binding proteins also appear to be gestation-
age related. Premature infants were found to have low
levels of serum vitamin D-binding protein. A strong
correlation was found between the serum 25-OHD3 levels and
serum D-binding protein levels. These levels remained low
and did not increase until the infants reached a post-
conceptional age equal to term.®^
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This study was designed to:
1) Determine the ontogeny of cytochrome P-450
activity;




Sperm positive Sprague Dawley female rats (Charles
River, Wilmington, Massachusetts), were placed on a vitamin
D-deficient diet (ICN Nutritional Biochemicals, Cleveland,
Ohio) on arrival. The diet contained 0.4% calcium and 0.4%
phosphorus.®^ The pregnant rats and lactating females were
anaesthetized with ethyl ether. Livers were removed and
subsequently placed in ice-cold 0.25 M sucrose. Fetuses and
neonates were anaesthetized and decapitated. Their livers
were immediately removed.
Materials
Crystalline vitamin D3 was obtained from Sigma Chemical
Company (St. Louis, Missouri). The vitamin D3 was
quantitated by ultraviolet spectroscopy at 265 nm on a
Lambda 3B Ultraviolet/Visible spectrophotometer (Perkin-
Elmer, Norwalk, Connecticut). Tritiated vitamin D3 [1,
2(n)-^H]-vitamin D3 (Amersham Corporation, Arlington
Heights, Illinois) was purified before use by high pressure
liquid chromatography (DuPont Company, Wilmington, Delaware)
by use of a Zorbax-Sil column (DuPont Company, Wilmington,
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Delaware) with hexane/isopropanol (98/2).®^ The 25-hydroxy-
vitamin D3 was a generous gift from Dr. M. Uskokovic
(Hoffman-LaRoche, Inc., Nutley, New Jersey) and Dr. John
Babcock (The Upjohn Company, Kalamazoo, Michigan). Glucose
6-phosphate dehydrogenase, ATP, Nicotinamide, and NADP'*’ were
obtained from Sigma Chemical Company (St. Louis, Missouri).
All organic solvents were analytical or HPLC grade.
Preparation of Microsomes
The livers were rinsed with ice-cold 0.25 M sucrose and
homogenized with 3 volumes of 0.25 M sucrose in a motor
driven glass Teflon Potter-Elvehjem homogenizer. The 25%
(w/v) liver homogenates were centrifuged at 10,000 g for the
high substrate experiments and 12,000 g for the low
substrate experiments for 15 minutes at 4°C. This initial
centrifugation sedimented mitochondria, nuclei, and cellular
debris.®^ The post-mitochondrial supernatant was
centrifuged at 105,000 g for 65 minutes at 4°C in an L8-70
ultracentrifuge (Beckman Instruments Inc., Palo Alto,
California) in order to produce a microsomal pellet and
cytosolic supernatant. The microsomal pellets were surface-
rinsed twice with 0.25 M sucrose and resuspended in a volume
of sucrose equal to the original post-mitochondrial
supernatant from which they were derived. Cytosolic
supernatant fractions were prepared by removing the fatty














supernatant was used. These prepared suspensions were
either used immediately for assay or were frozen and stored
at -60°C in a Queue Cryostar freezer (Queue Systems,
Parkersburg, West Virginia) for further use.
Incubation Procedures
The incubation conditions for assay of microsomal
vitamin D3 25-hydroxylase activity were similar to
previously published methods. ' Microsomal suspensions of
2.5 ml were incubated in the presence of 2.5 ml cytosolic
fraction, 2.5 ml of buffered cofactor solution (0.1 M
potassium phosphate buffer, 0.4 mM NADP"*", 160 mM
nicotinamide, 20 mM ATP, and 22.4 mM glucose 6-phosphate
adjusted to pH 7.4), and 2.5 ml salt solution (5 mM MgCl2
and 0.1 M KCl). Two units of glucose 6-phosphate
dehydrogenase in 2 0 ul of water was added to each sample.
Each flask was gassed with oxygen/carbon dioxide (95/5) for
one minute after which ^H-vitamin D3 (44 nM, 3.0 x 10^ dpm)
was added in 20 ul of ethanol. The flasks were capped and
incubated in a Dubnoff shaking incubator for two hours at
37°C. Previous studies have shown that under the incubation
conditions described, the reaction velocity varies linearly
with time for at least three hours.^^'®^ The incubation
flasks contained an average of 11 mg microsomal protein
(adult females) and 42 mg cytosolic protein (adult females).
In selected incubations 0.25 M sucrose was substituted for
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Scheme II2.5ml Cytosol (42 mg protein)2.5ml Microsomes (11 mg protein)2.5ml Cofactor Solution
(0.1 M Potassium Phosphate buffer, 0.4 mM NADP"^,
160 mM Nicotinamide, 20 mM ATP, and 22.4 mM Glucose
6-Phosphate, adjusted to pH 7.4)2.5ml Salt Solution
(5 mM MgCl2 and 0.1 M KCl)
20 ul Glucose 6-phosphate dehydrogenase (2.0 units)
20 ul [^H] vitamin D3
(44 nM, 3 X 10^ dpni)
Flasks were flushed with O2/CO2 (95/5) for one minute and
incubated for 2 hours at 37°C.
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the cytosolic fraction. In most experiments boiled
microsomes, incubated in the same manner as unboiled
microsomes, served as controls. Samples of unboiled
microsomes that contained no D3 served as controls in some
experiments. The reactions were terminated by the addition
of 10 ml cyclohexane/ethyl acetate (1/1).
The incubation mixtures were extracted once with two
volumes of cyclohexane/ethyl acetate (1/1) and once with
three volumes of ethyl ether, passed first over an alumina
column. The extracts were combined and evaporated under
nitrogen.
Some modifications in the incubation procedure were
adhered to in the experiments at high substrate
concentration of D3. Vitamin D3 at a level of 6.5 uM (25 ug
dissolved in 20 ul of ethanol) was incubated with the
previously stated components. Two minutes prior to
termination of the incubations 1500 cpm of ^H-250HD3 in
ethanol was added to each sample in order to monitor
recovery.
Chromatography
The lipid extracts were chromatographed on aluminum-
backed silica gel 60 F254 thin layer chromatography plates
(E. Merck, Darmstadt, West Germany). The lipid extracts
from the incubation mixtures were spotted onto the plates
under a light flow of nitrogen. Four samples, 3 centimeter
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wide bands each, were spotted on 20 x 20 centimeter TLC
plates. The samples were separated from each other by a
distance of one centimeter. Synthetic vitamin D3 and 25-
hydroxyvitamin D3 were spotted in the center of each plate
and served as standards. The plates were developed in
chloroform/ethyl acetate (4/1) for 90 minutes. The
migration distance was 14 centimeters. Vitamin D3 and 25-
OHD3 were sufficiently separated. Rp, values for vitamin D3
and 25-OHD3 were 0.70 and 0.36, respectively. The standards
were viewed under an ultraviolet lamp at 254 nm.
The area on each thin layer chromatogram that
corresponded to 25-OHD3 for a given sample was scraped into
a 5.25 inch Pasteur pipette packed with glass wool.
Radioactivity was eluted from the silica with 7 mis of ethyl
acetate. The ethyl acetate extracts of the 25-OHD3 regions
were evaporated under nitrogen and resuspended in 100 ul of
hexane/isopropanol (94/6). The samples were chromatographed
on a Zorbax-Sil HPLC column (0.45 x 25 cm) with
hexane/isopropanol (94/6) at a flow rate of 1 ml/minute.
Synthetic 25-hydroxyvitamin D3 served as a standard.
Ultraviolet absorption of the non-radioactive 25-OHD3
standard was monitored at 254 nm with an 860 Absorbance
Detector (Dupont Company, Wilmington, Delaware) and an LDC
CI-10 Integrator (Laboratory Data Control, Riviera Beach,
Florida). Peak absorbance of synthetic 25-OHD3 was at 10.5
minutes. Radioactivity in the samples was monitored by
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collecting (2070 Ultrorac II, LKB Producker AB, Bromma,
Sweden) and counting twenty one ml fractions during elution
of the sample from the column. The fractions were
evaporated, dissolved in Scintilene scintillation fluid
(Fisher Scientific Co., Fair lawn, New Jersey), and counted
in a Model LS 5801 Liquid Scintillation Counter (Beckman
Instruments, Inc., Palo Alto California).
The remainder of each thin layer chromatogram was
sectioned into six or more parts from origin to front. The
sections were cut into 20 ml counting vials and counted in a
Model 5801 Liquid Scintillation Counter (Beckman
Instruments, Inc., Palo Alto, California) using Ready-Solv
MP counting solution (Beckman Instruments, Inc., Palo Alto,
California). Disintegrations per minute were calculated for
all samples counted using a stored standard curve, external
standardization. The radioactivity found on the remainder
of the chromatogram was added to that obtained on each HPLC
chromatogram in order to compute recovery. The
radioactivity in the 25-OHD3 peak was corrected for
recovery. The specific activity of the incubated vitamin D3
was used to calculate the number of picomoles produced.
Experimental samples incubated with non-radioactive
vitamin D3 were processed somewhat differently. The regions
on the TLC chromatographs were extracted with 7 mis of ethyl
acetate, evaporated under nitrogen and chromatographed on a




A) 2 volumes of cyclohexane/ethyl acetate (1/1)
B) 3 volumes ether
2) TLC of lipid extracts on silica gel with chloroform/
ethyl acetate (4/1)
3) HPLC of 25-OHD3 region from (2) on a Zorbax-Sil silica
column with hexane/isopropanol (94/6)
4) Liquid scintillation counting of fractions from (3) .
Sectioning and counting of TLC plates to assess recovery
of radioactivity.
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flow rate of one ml/minute. Synthetic 25-OHD3 was injected
separately to determine the elution position of 25-OHD3.
The peak area of the samples of 25-OHD3 was calculated by
the use of the LDC CI-10 Integrator (Laboratory Data
Corporation, Riviera Beach Florida). A standard curve
correlating peak area with nanograms of 25-OHD3 was used to
calculate the amount of 25-OHD3 produced.®® The
experimental peaks were recovered in 7 ml counting vials,
dried down, and dissolved in 3a70B* Scintillation Cocktail
(Research Products Corp., Mount Prospect, Illinois).
Disi^fegrations per minute were calculated using a Model LS
5801 quid Scintillation system (Beckman Instruments, Palo
Alto, California). The values were used to determine
ne*!-
reco'^^y of the radioactive 25-OHD3 added at the end of the
is i
incui/i^ions.
The regions of the TLC chromatograms corresponding to
vitamin D3 were processed as were the 25-OHD3 samples. They
were chromatographed on a column using initially
hexane/isopropanol (96/4), then hexane/isopropanol (98/2).
Recovery of vitamin D3 was also calculated for each sample
in order to determine the extent of substrate degradation.
Protein was determined by the method of Lowry with bovine
serum albumin as the standard.®^ The probability of
difference between two means was determined by a two tailed
t test.
RESULTS
Analytical methods used in this 25-OHD3 study included
ultracentrifugation, lipid extractions, thin layer
chromatography followed by high pressure liquid
chromatography, and liquid scintillation counting. These
procedures were necessary to quantitate the amount of 25-
hydroxyvitamin D3 formed in the incubation procedures.
Thin layer chromatography analysis showed that there
was a marked migratory difference between vitamin D3 and its
product, 25-OHD3. The Rp values calculated were 0.70 and
0.36 respectively. In analyzing the remainder of the thin
layer chromatograms, there was not a significant difference
in the distribution of radioactivity from experimental and
control samples. This is indicative of a lack of enzymatic
conversion of vitamin D3 to other by-products.
High performance liquid chromatography was on a
Zorbax-Sil column with hexane/isopropanol (94/6). As is
illustrated in Figure 5A, a clearly defined peak of
radioactivity co-migrated with synthetic 25-OHD3.
Control samples containing boiled microsomes were
incubated and analyzed in the same manner as the
experimental samples. On analysis, the controls produced
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Figure 5. Pattern of radioactivity for 25{OH)D3. Microsomes
were incubated as indicated under Experimental Procedure
with cytosol (A) and alone (B). The incubation mixtures
were extracted for lipids, purified initially by TLC, and
chromatographed on a normal phase HPLC column with
hexane/isopropanol (94/6). The arrows indicate the time of
elution of synthetic 25-OHD3.
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flat baselines. No evidence of 25-OHD3 was found in these
samples. This implies that the radioactive peak seen is due
solely to the enzymatic conversion of vitamin D3 to 25-OHD3.
In these experiments a few developmental aspects of
vitamin D3 25-hydroxylase activity were examined in liver
microsomes of rat fetuses. A comparison of 25-OHD3 liver
microsomal production was made between fetuses and their
mothers (Table 1). The substrate concentration used in this
study was equal to the Kjjj(44nM) for the vitamin 03.^^
Unsuccessful attempts were made to quantitate nonradioactive
25-OHD3 production by ultraviolet absorbance at 254 nm. The
use of saturating levels of radioactive substrate was
impractical. 25-Hydroxyvitamin D3 production was examined
in mothers and fetuses three days prior to parturition and
on the expected day of parturition. 25-Hydroxyvitamin D3
production by liver microsomes from mothers went from a
value of 0.22 pmol/mg microsomal protein/hour 3 days prior
to parturition to a value of 0.54 pmol/mg protein/hour on
the expected day of parturition.
Vitamin D3 25-hydroxylase activity was low in fetuses
but increased with increasing fetal age (Table 1). Three
days prior to birth activity in fetuses was two percent of
that of their mothers (0.11 pmol/g liver/hour for fetuses
compared with 5.4 pmol/g liver/hour for mothers). By day
zero, fetal hydroxylase activity had increased to thirteen
percent of that of their mothers (1.2 pmol/g liver/hour for
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Table 1. Development of Vitamin D3 25-Hydroxylase
Activity in Rat Liver Microsomes
25-OHD.3 Production, Mean + SD
Experimental
Animal
pmol/g 1iver/h pmol/mg protein/h
-3 day
Offspring 0.11 + 0.01 0.006 + 0.001
Mothers 5.4 + 1.1 0.22 1+ 0 • 0 4:0
0 day
Offspring 1.2 + 0.2 0.09 ± 0*01
Mothers 9.3 + 0.2 0.54 + 0.02
Values are mean + SD for 2-3 incubations of pooled
microsomes and cytosol from 5-9 litters and their mothers.
Microsomes and cytosol were incubated as described under
Experimental Procedure.
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fetuses compared with 9.3 pmol/g liver/hour for mothers).
Production of 25-hydroxyvitamin D3 was calculated both
on a gram liver basis (pmol/g liver/h) and on a mg protein
basis (pmol/mg protein/h). Protein values are much lower in
the fetal stages and an apparent higher value of 25-OHD3
production is calculated when production is on a mg protein
basis.
A liver cytosolic factor has been determined in this
study to play an important role in the metabolism of vitamin
D3 by microsomes from fetuses (Table 2). In the
incubations, microsomal and cytosolic levels were present in
the same proportion as that which normally exists in the
liver. The cytosolic factor was obligatory for activity in
the fetuses analyzed (-3 and 0 day offspring). The
cytosolic factor had a stimulatory effect on the 25-
hydroxylase reaction in mothers (Table 3). This factor
stimulated the 25-hydroxylase reaction 1.6- to 1.7-fold.
Fetal cytosol when added to maternal microsomes stimulated
the 25-hydroxylase reaction to the same extent as maternal
cytosol (Table 3).
It was found that 91% to 97% of the total recovered
radioactivity at the end of the incubation period co¬
migrated with synthetic vitamin D3 when fetal and maternal
microsomes were incubated with corresponding cytosol. The
values varied from 77% to 97% when fetal and maternal
microsomes were incubated alone (Table 4). When microsomes
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Table 2. The Role of Cytosol in the Metabolism of Vitamin
D3 by Liver Microsomes of Rat Fetuses
25-OHD3 Production (pmol/g liver/h)
Age (Days)
of Offspring - cytosol + cytosol
-3 0 0.11 + 0.02
0 0 1.20 + 0.20
Values are mean + SD for 2-3 incubations of pooled
microsomes from 5-9 rat litters. Incubation conditions were
as described in Experimental Procedure.
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Table 3. The Effect of Fetal Cytosol on the Vitamin D3
25-Hydroxylase Activity of Their Mothers
25-OHD3 Production (pmol/mg protein/h)
Age (Days)
of Fetuses - cytosol + cytosol
fetal
+ cytosol
-3 0.14 + 0.03^ 0.22 + 0.04 0.20 + 0.03
0 0.32 + 0.04^ 0.54 + 0.02 0.53 + 0.01
Liver microsomes from the mothers were incubated as in
Experimental Procedure. Value are mean + SD of 2-3
incubations of pooled microsomes and cytosol from 5-9
litters and their mothers.
^p < 0.01 when compared with the mean value of
microsomes incubated with cytosol.
^p < 0.002 when compared with the mean value of
microsomes incubated with cytosol.
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Table 4. Total Degradation of Vitamin D3 as Determined
From HPLC and TLC Chromatograms
% of Total Radioactivity
Recovered in the D3 Spot
Incubation Conditions Age (Days) of Offspring
-3 0
Maternal microsomes
- cytosol 95.3 + 0.7 88.9 + 2.8
+ cytosol 95.3 + 0.6 92.4 + 1.0
+ fetal cytosol 94.2 + 0.2 89.4 ± 1-4
Fetal microsomes
- cytosol 96.5 + 0.4 81.4 + 3.4^
+ fetal cytosol 95.9 + 1.7 92.6 ± 1-1
Liver microsomes and cytosol from fetuses and mothers were
incubated as under Experimental Procedure. Values are mean
+ SD of 3 incubations of microsomes and cytosol from 5-9
fetal litters and their mothers.
^p < 0.0001 when compared with the mean value of microsomes
incubated with cytosol.
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were incubated without cytosol non-specific radioactivity
surrounded the 25-OHD3 peak on HPLC chromatograms (Figure
5B). This radioactivity was either significantly reduced or
not present at all when microsomes were incubated with
cytosol (Figure 5A). The non-specific oxidation present on
HPLC chromatograms of incubation samples from fetuses is
quantified in Table 5.
Degradation varied from experiment to experiment and
was different for fetal microsomes and maternal microsomes.
Degradation for -3 day fetuses and adults was minimal
whether or not cytosol was present. Degradation was greater
in 0 day studies than in the -3 day experiments and zero day
fetuses had much greater degradation than their mothers.
Cytosolic fractions from fetuses were fully capable of
reducing degradation when incubated with fetal microsomes.
Experiments were also performed using high substrate
(6.5 uM) concentrations of vitamin D3 in incubation mixtures
of liver microsomes and cytosol. The vitamin D3
concentration was 15-fold greater than that which has been
determined to be saturating for the microsomal 25-
hydroxylase. The same analytical methods used in the low
substrate experiments were used in these studies, with some
variations. 25-Hydroxyvitamin D3 production was detected by
ultraviolet absorbance at 254 nm. The peak area of the
experimental 25-OHD3 peaks was calculated using an LDC CI-10
Integrator. In these experiments activity was first seen at
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Table 5. The Effect of Cytosol on the Degradation of
Vitamin D3
% Non-25-OHD3 Activity on
HPLC Chromatograms
Incubation Conditions Age (Days) of Offspring
-3 0
Fetal microsomes
- cytosol 0.21 + 0.06 1.9 + 1.0
+ fetal cytosol 0 0
Liver microsomes and cytosol from fetuses and mothers were
incubated as under Experimental Procedure. Results are
expressed as the percentage of total recovered radioactivity
on the HPLC chromatograms which did not comigrate with 25-
OHD3. Values are mean + SD of 3 incubations of microsomes
and cytosol pooled from 5-9 fetal litters and their mothers.
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Day 0 as opposed to Day -3 in the low substrate studies
(Table 6). Fetal 25-hydroxylase activity was not seen in -3
day or -1 day fetuses. Development of significant levels of
activity at high substrate appears to proceed at a faster
rate than at low substrate. This is evident when one
compares 0 day offspring at high and low substrate levels.
Activity is forty percent of that of their mothers at high
substrate (12.58 pmol/g liver/h for fetuses compared with 32
pmol/g liver/h for mothers). In low substrate 0 day studies
fetal activity is thirteen percent of that of their mothers
(1.2 pmol/g liver/h for fetuses compared with 9.3 pmol/g
liver/h for mothers).
Contrary to the low substrate studies cytosol appears
to play no role in the enhancement of 25-hydroxylase
activity when high substrate is used. There was no
significant effect of cytosol on 25-hydroxylase activity in
fetuses when high substrate was used. There was also no
significant difference in 25-hydroxylase activity of
maternal microsomes studied relative to the absence or
presence of the cytosolic fraction. Fetal cytosol also had
no stimulatory effects on the 25-hydroxylase activity of
microsomes from mothers (Table 7).
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Table 6. Development of Vitamin D3 25-Hydroxylase
Activity in Rat Liver Microsomes at High
Substrate Concentrations
25-OHD3 Production, Mean + SD
Experimental
Animals
pmol/g liver/h pmol/mg protein/h
-3 day
Offspring 0 0
Mothers 35.5 + 2.2 2.3 + 0.3
-1 day
Offspring 0 0
Mothers 42.5 + 1.2 2.6 + 0.3
0 day
Offspring 12.8 + 4.8 0.69 + 0.1
Mothers 32.0 + 5.4 2.1 + 0.4
Values are mean + SD for 2-5 incubations of pooled
microsomes and cytosol from 6-8 litters and their mothers.
Microsomes and cytosol were incubated as described under
Experimental Procedure.
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Table 7. The Effect of Cytosol on the Vitamin D3 25-
Hydroxylase Activity in Liver Microsomes
Incubated at High Substrate Concentrations.
25-OHD3 Production (pmol/mg protein/h)
Age (Days)
of Fetuses - cytosol + cytosol
fetal
+ cytosol
-3 2.3 + 0.8 2.3 + 0.3 2.1 + 0.1
0 2.2 + 0.7 2.6 + 0.3 2.2 + 0.2
Liver microsomes from the mothers were incubated as in
Experimental Procedure. Values are mean + SD of 2-3
incubations of pooled microsomes and cytosol from 6-8
litters and their mothers.
DISCUSSION
The specific aims of this study have been to determine
the ontogeny of the liver microsomal vitamin D3 25-
hydroxylase and of the liver cytosolic factor which enhances
its activity.
Vitamin D3 25-hydroxylase activity was very low in -3
day old offspring and increased gradually with increasing
fetal age. Further laboratory studies on development of 25-
hydroxylase activity showed that production appeared to be
fairly constant on days 2 and 7 and increased on day 15. °
Activity increased 6-fold between day 15 and 22 to a value
twice that of the activity in maternal microsomes.°° By day
29, activity in the neonates had dropped to a value equal to
that of the mothers at day 22. Full maturation was, thus,
reached at or near weaning. Studies on the development of
the liver microsomal vitamin D3 25-hydroxylase have been
recently reported by Plourde ^ They found that the
liver capacity for 25-hydroxylation of vitamin D3 was
present in the rat fetus during the fetal period. They
showed that activity increased linearly to a maximum level
by 3 days of chronological age and remained unchanged.
However, 25-hydroxyvitamin D3 production was not determined
39
40
between day 15 and day 30.^® Fetal production rate of 25-
hydroxyvitamin D3 was several fold lower in Plourde's
studycompared to the values determined in this study.®®
Bhattacharya and DeLuca^ showed that the liver
cytosolic factor was necessary for the activity of the liver
vitamin D3 25-hydroxylase and must be added to the
microsomal fractions. Vitamin D3 was found to be
oxidatively degraded when cytosol was excluded from the
incubation medium.^ Their studies showed that at low
substrate concentrations, the liver cytosolic factor both
enhanced 25-hydroxylase activity and inhibited vitamin D3
degradation. Their laboratory found no 25-hydroxylase
activity in the absence of the cytosolic factor. Results of
this laboratory's studies are in agreement with the
conclusion of Bhattacharya and DeLuca.® However, 25-OHD3
production was detected in the absence of cytosol, but to a
lesser extent than when cytosol was included in the
incubation mixtures. Cytosol was able to stimulate the rate
of 25-hydroxylation in maternal microsomes from 1.6- to 1.7-
fold. With the advent of more sophisticated and sensitive
analytical techniques quantification of 25-OHD3 production
is more accurate. This may account for our laboratory
detecting 25-OHD3 production in the absence of cytosol when
the past studies did not observe production.
The cytosolic factor was obligatory for 25-hydroxylase
activity in the fetuses examined. The cytosolic factor,
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from fetuses as young as -3 days old, was found to be
capable of enhancing the 25-hydroxylase activity of maternal
microsomes. Further studies have shown that the cytosolic
factor stimulates 25-hydroxylase in neonates. ° The
cytosolic factor is not very well characterized. This leads
one to hypothesize about the mechanism of action of this
factor in stimulating 25-OHD3 production. It has been
thought that the cytosolic factor allows a more specific
interaction between vitamin D3 and the 25-hydroxylase.^ It
may be that the factor, in some manner, can make more
substrate available to the hydroxylase or there may be some
mode of action in which the substrate is in a more stable
state. In these experiments degradation of vitamin D3 was
reduced when fetal cytosol was incubated with fetal
microsomes.
The ontogeny of the vitamin D3 25-hydroxylase was also
determined at high substrate concentrations of vitamin D3.
Contrary to the low substrate studies no 25-OHD3 production
was detected on Day -3 and Day -1. Activity was initially
detected on Day 0 at a value which represented 4 0% of the
activity of their mothers on that same day. Although the
method of detecting 25-OHD3 was less sensitive than that for
the low substrate experiments, the lack of activity in the
fetuses at Day -1, but the presence of 40% activity at Day 0
suggest that development under these conditions is more
abrupt and rapid than at low substrate. If development of
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activity had been gradual, activity would have been detected
at Day -1. Differences in development in the low and high
substrate studies (40% fetal activity at high substrate vs.
13% fetal activity at low substrate in 0 day fetuses)
suggest that two different microsomal enzyme systems may be
involved in the microsomal hydroxylation of vitamin D3.
Bjorkhem and Holmberg^® developed a specific assay for
25-hydroxylation of vitamin D3 in microsomes. The assay was
used to determine enzyme activity at greater than substrate
saturation levels. Under these conditions the hydroxylation
rate was 100-fold higher than that observed by Madhok and
DeLuca.^^ In contrast to the findings by Bhattacharya and
DeLuca,^ enzyme activity was not dependent upon the added
cytosolic factor. These results from studies using high
substrate concentrations of vitamin D3 in incubation
mixtures utilizing liver microsomes and cytosol have also
shown that there is no significant cytosolic effect on
enzyme activity.
In the studies conducted with low substrate levels,
vitamin D3 25-hydroxylase activity was present as early as
three days before birth and began to increase with fetal
age. Examination of the role of the cytosolic factor showed
that the cytosolic fraction from as early as -3 day old
offspring was capable of stimulating 25-hydroxylase activity
in maternal microsomes. Fetal cytosol was also capable of
reducing degradation of vitamin D3. These observations and
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the finding that 25-hydroxylase activity reaches full
maturation at or near weaning suggest that the development
of the cytochrome P-450 vitamin D3 25-hydroxylase is the
rate limiting factor in the maturation of 25-hydroxylase
activity in liver microsomes. Clinical relevance of the
studies must be determined. It is still uncertain as to
whether this cytosolic factor(s) does play a role in
sequestration of vitamin D3 within the cell in vivo.
Further studies of interest include characterization of the
cytosolic factor(s). At high substrate levels vitamin D3
25-hydroxylase was present initially in 0 day old offspring
at a level which was 40% of that of their mothers. The
cytosolic factor had no stimulatory effect on the 25-
hydroxylase activity. Kinetics studies are needed to
determine if indeed two microsomal 25-hydroxylase systems
are in play.
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